Funds that concentrate investments in specific industries, sectors, markets or asset classes may underperform or be more volatile than other industries, sectors, markets or asset classes and than the general securities market.
We believe biotech's long-term historical drivers, demographics and mergers and acquisitions (M&A) activity to secure patent protected drugs, may outlast near-term political headwinds and should lead investors to consider bio-pharma from a longer-term perspective. Biotech valuations also currently appear attractive relative to the broader market and look less crowded than other growth sectors. Over the short term we see potential opportunities in select individual biotech and pharma names.
Biotech has historically been driven by long-term growth prospects. Investors have historically focused on two key long-term drivers: aging demographics and strong pricing power via patent protected drugs. The importance of these trends has not diminished, however the market's focus on these trends has diminished recently, focusing instead on political headlines.
Since September 2015, the bio-pharma industry has increasingly become a rhetorical target of politicians focused on drug pricing. Investors grew increasingly cautious as politicians from both sides adopted a tougher regulatory attitude towards drug pricing, leading bio-pharma gains to become increasingly punctuated by sharp, bearish reversals on political headlines. This led many bio-pharma names to decouple from the broader momentum names.
Biotech's correlation to momentum has broken down
Source: Thomson Reuters, 7/21/2017. The time series shown is the 90-day rolling correlation between the MSCI USA Momentum Index and the Nasdaq Biotechnology Index. Correlation is a statistical measure that captures the degree of the historical relationship between the returns of a pair of investments or indexes. Correlation ranges between +1 and -1. A correlation of +1 indicates returns moved in tandem, -1 indicates returns moved in opposite directions, and 0 indicates no correlation.
Don't overlook the secular trends
Just as investors pivoted out of bio-pharma names due to near-term regulatory risks, they rotated back in following President Trump's election with the expectation of deregulation. Those expectations may pay off, but investors appear to be missing the broader point; trading around political headlines has come at the expense of focusing on potentially favorable secular trends – aging population and M&A activity to secure new drug patents, which may offer significant pricing power. We believe those trends could remain over the long-term. The market's distraction with short-term matters may offer opportunities for long-term growth investors. The aging of patent protected drugs could lead to an increase in M&A as companies look to maintain their pricing power. Investors may want to ignore the near-term headwinds and refocus their attention to the long-term growth trends.